Emerging cell therapies in the vasculitis field

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• ANCA vasculitis is a small-vessel vasculitis driven by autoantibodies to MPO or PR3.
• Current broad-spectrum immunosuppression is effective but increases infection susceptibility.
• Understanding of disease pathogenesis, including autoantigen specificity and immune cell roles, has advanced.

Purpose of the Study:

• To review the current research landscape for novel antigen- and cell-specific therapies in ANCA vasculitis.
• To explore emerging therapeutic strategies beyond conventional immunosuppression.

Main Methods:

• Review of current scientific literature on ANCA vasculitis pathogenesis and therapeutics.
• Analysis of potential new treatment modalities targeting specific immune components.

Main Results:

• Research has identified key autoantigens (MPO, PR3) and immune cell subsets involved in ANCA vasculitis.
• Several promising cell-specific therapeutic avenues are emerging, including bispecific antibodies, tolerogenic liposomes, and engineered T cells.
• Restoring regulatory T-cell function is a potential strategy for prolonged remission.

Conclusions:

• The field is advancing towards more targeted therapies for ANCA vasculitis.
• Emerging cell-based therapies offer potential for improved efficacy and reduced side effects.
• Further investigation into these novel approaches is warranted.